{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:56:44Z","timestamp":1789073804560,"version":"build-2803163510"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>This meta-analysis aimed to summarize the available evidence to compare angiotensin-converting enzyme (ACE) inhibitors with angiotensin II receptor blockers (ARBs) on improving insulin sensitivity in hypertensive patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Randomized controlled trials (RCTs) comparing ACE inhibitors versus ARBs published with outcomes on homeostasis model assessment of IR (HOMA-IR), glucose infusion rate (GIR), the quantitative insulin sensitivity check index (QUICKI), insulin sensitivity index (ISI) composite, fasting plasma glucose (FPG), fasting plasma insulin (FPI), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were searched through 5 databases. Data were searched from their inception to July 5, 2020. Stata 14.0 was used to perform the meta-analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Eleven RCTs (n = 1015) were included in this meta-analysis. Pooled analysis of studies showed no significant difference in HOMA-IR between ARBs and ACE inhibitors (WMD = -0.09, 95% CI: -0.69 to 0.50, P = 0.755); however, subgroup analysis of therapeutic duration showed a significant difference in HOMA-IR between ARBs and ACE inhibitors among the long-term intervention subgroup (&gt;12 weeks) (WMD = 0.41, 95% CI: 0.06 to 0.76, P = 0.022) and hypertensive patients with diabetes mellitus subgroup (WMD = 0.55, 95% CI: 0.49 to 0.61, P &lt; 0.001); results showed no significant difference between ARBs and ACE inhibitors on QUICKI score (WMD = -0.00, 95% CI: -0.03 to 0.03, P = 0.953) in hypertensive patients; however, the efficacy of ACE inhibitors on improving GIR and ISI composite was significantly better than that of ARBs (WMD = -1.09, 95% CI: -1.34 to -0.85, P &lt; 0.001; WMD = -0.80, 95% CI: -1.24 to -0.36, P &lt; 0.001, respectively). Furthermore, no significant differences were noted on FPG (WMD = 0.72, 95% CI: -1.39 to 2.83, P = 0.505), FPI (WMD = -0.48, 95% CI: -1.60 to 0.64, P = 0.398), SBP (WMD = -0.65, 95% CI: -1.76 to 0.46, P = 0.254), and DBP (WMD = -0.30, 95% CI: -1.70 to 1.10, P = 0.675) between ARBs and ACE inhibitors.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Results from this meta-analysis showed that ACE inhibitors resulted in more effective improvement of HOMA-IR compared with ARBs among the long-term intervention and hypertensive patients with DM subgroup; furthermore, the efficacy of ACE inhibitors on improving GIR and ISI composite was significantly better than that of ARBs in hypertensive patients. However, ARBs had no significant difference in QUICKI score, FPG, FPI, SBP, and DBP compared with ACE inhibitors. Larger and better-designed studies are needed to further verify this conclusion.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0253492","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:13:21Z","timestamp":1625703201000},"page":"e0253492","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers on insulin sensitivity in hypertensive patients: A meta-analysis of randomized controlled trials"],"prefix":"10.1371","volume":"16","author":[{"given":"Jia","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2711-3481","authenticated-orcid":true,"given":"Guanjie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"issue":"8","key":"pone.0253492.ref001","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11886-016-0755-4","article-title":"Genetics of Insulin Resistance and the Metabolic Syndrome","volume":"18","author":"AE Brown","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"pone.0253492.ref002","first-page":"1545","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015. A systematic analysis for the Global Burden of Disease Study","volume":"2016","author":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"pone.0253492.ref003","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2310\/JIM.0b013e31828298ce","article-title":"Inhibition of renin-angiotensin system: implications for diabetes control and prevention","volume":"61","author":"SS Prabhakar","year":"2013","journal-title":"J Investig Med"},{"issue":"3 Pt 2","key":"pone.0253492.ref004","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/01.HYP.0000051891.90321.12","article-title":"Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-alpha","volume":"41","author":"ED Motley","year":"2003","journal-title":"Hypertension"},{"issue":"10","key":"pone.0253492.ref005","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1097\/00004872-200410000-00021","article-title":"Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity","volume":"22","author":"M Furuhashi","year":"2004","journal-title":"J Hypertens"},{"issue":"2","key":"pone.0253492.ref006","doi-asserted-by":"crossref","first-page":"E353","DOI":"10.1152\/ajpendo.00402.2004","article-title":"Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression","volume":"288","author":"MC Blendea","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"pone.0253492.ref007","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.biopha.2018.10.191","article-title":"The renin-angiotensin system as a target to solve the riddle of endocrine pancreas homeostasis","volume":"109","author":"F Graus-Nunes","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"pone.0253492.ref008","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.diabres.2014.11.007","article-title":"A meta-analysis of the effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on insulin sensitivity in hypertensive patients without diabetes","volume":"107","author":"Y Yang","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"issue":"24","key":"pone.0253492.ref009","doi-asserted-by":"crossref","first-page":"e20674","DOI":"10.1097\/MD.0000000000020674","article-title":"The efficacy of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on insulin resistance in hypertensive patients: A protocol for a systematic review and meta-analysis","volume":"99","author":"J Yao","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"pone.0253492.ref010","first-page":"151","article-title":"1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee","volume":"17","year":"1999","journal-title":"J Hypertens"},{"issue":"4","key":"pone.0253492.ref011","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jacc.2014.06.014","article-title":"2014 hypertension recommendations from the eighth Joint National Committee (JNC-8) panel members raise concerns for elderly black and female populations","volume":"64","author":"LR Krakoff","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"pone.0253492.ref012","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report","volume":"289","author":"AV Chobanian","year":"2003","journal-title":"JAMA"},{"issue":"Suppl 1","key":"pone.0253492.ref013","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc20-S002","article-title":"Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"key":"pone.0253492.ref014","author":"World Health Organization, International Diabetes Federation","year":"2006","journal-title":"Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO\/IDF consultation"},{"issue":"16","key":"pone.0253492.ref015","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"KG Alberti","year":"2009","journal-title":"Circulation"},{"key":"pone.0253492.ref016","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1741-7015-9-48","article-title":"Metabolic syndrome: definitions and controversies","volume":"9","author":"E Kassi","year":"2011","journal-title":"BMC Med"},{"issue":"6","key":"pone.0253492.ref017","first-page":"569","article-title":"Metabolic syndrome in type 2 diabetes: comparison of WHO, modified ATPIII & IDF criteria","volume":"62","author":"A Ahmed","year":"2012","journal-title":"J Pak Med Assoc."},{"issue":"9","key":"pone.0253492.ref018","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.jhh.1002201","article-title":"Validity and reproducibility of HOMA-IR, 1\/HOMA-IR, QUICKI and McAuley\u2019s indices in patients with hypertension and type II diabetes","volume":"21","author":"PA Sarafidis","year":"2007","journal-title":"J Hum Hypertens"},{"issue":"7","key":"pone.0253492.ref019","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","article-title":"Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans","volume":"85","author":"A Katz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"pone.0253492.ref020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1358863X13515766","article-title":"Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"A Sahebkar","year":"2014","journal-title":"Vasc MedFeb"},{"key":"pone.0253492.ref021","article-title":"Cochrane handbook for systematic reviews of interventions version 5.0. 2","author":"J Higgins","year":"2010","journal-title":"The Cochrane Collaboration, 2009"},{"issue":"5\u20136","key":"pone.0253492.ref022","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00228-005-0931-8","article-title":"Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension","volume":"61","author":"F Anan","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"pone.0253492.ref023","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1161\/01.HYP.0000040264.15961.48","article-title":"ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time","volume":"40","author":"NJ Brown","year":"2002","journal-title":"Hypertension"},{"issue":"7","key":"pone.0253492.ref024","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0149-2918(03)80201-1","article-title":"A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus","volume":"25","author":"G Derosa","year":"2003","journal-title":"Clin Ther"},{"issue":"9 Pt 1","key":"pone.0253492.ref025","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0895-7061(01)02140-9","article-title":"Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women","volume":"14","author":"R Fogari","year":"2001","journal-title":"Am J Hypertens"},{"issue":"4","key":"pone.0253492.ref026","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/hr.2010.260","article-title":"Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension","volume":"34","author":"R Fogari","year":"2011","journal-title":"Hypertens Res"},{"issue":"6","key":"pone.0253492.ref027","doi-asserted-by":"crossref","first-page":"667","DOI":"10.5603\/EP.a2018.0068","article-title":"The effect of short-term perindopril and telmisartan treatment on circulating levels of anti-inflammatory cytokines in hypertensive patients","volume":"69","author":"W Gilowski","year":"2018","journal-title":"Endokrynol Pol"},{"issue":"12","key":"pone.0253492.ref028","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/eurheartj\/ehm101","article-title":"Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients","volume":"28","author":"KK Koh","year":"2007","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0253492.ref029","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijcard.2008.11.017","article-title":"Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs","volume":"140","author":"KK Koh","year":"2010","journal-title":"Int J Cardiol"},{"issue":"11","key":"pone.0253492.ref030","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1097\/HJH.0000000000001079","article-title":"Fixed-dose combination of zofenopril plus hydrochlorothiazide VS. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome)","volume":"34","author":"ZAMES (Zofenopril in Advanced MEtabolic Syndrome) Study Group","year":"2016","journal-title":"J Hypertens"},{"issue":"12","key":"pone.0253492.ref031","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1097\/HJH.0b013e328312677e","article-title":"Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives","volume":"26","author":"RA Sanchez","year":"2008","journal-title":"J Hypertens"},{"issue":"3","key":"pone.0253492.ref032","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3317\/jraas.2003.032","article-title":"Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients","volume":"4","author":"D Yavuz","year":"2003","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"2","key":"pone.0253492.ref033","doi-asserted-by":"crossref","first-page":"H787","DOI":"10.1152\/ajpheart.00974.2005","article-title":"Hyperinsulinemia: effect on cardiac mass\/function, angiotensin II receptor expression, and insulin signaling pathways","volume":"291","author":"AM Samuelsson","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"pone.0253492.ref034","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1210\/en.2008-1018","article-title":"Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes","volume":"150","author":"T Wada","year":"2009","journal-title":"Endocrinology"},{"issue":"2","key":"pone.0253492.ref035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11906-008-0019-9","article-title":"Local adipose tissue renin-angiotensin system","volume":"10","author":"LA Cassis","year":"2008","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"pone.0253492.ref036","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"PA James","year":"2014","journal-title":"JAMA"},{"issue":"Suppl 1","key":"pone.0253492.ref037","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.2337\/diab.45.1.S110","article-title":"Potential role of bradykinin in forearm muscle metabolism in humans","volume":"45","author":"GJ Dietze","year":"1996","journal-title":"Diabetes"},{"issue":"3","key":"pone.0253492.ref038","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/01.HYP.0000028979.98877.0C","article-title":"ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO","volume":"40","author":"T Shiuchi","year":"2002","journal-title":"Hypertension"},{"issue":"4","key":"pone.0253492.ref039","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","article-title":"Diabetes, hypertension, and cardiovascular disease: an update","volume":"37","author":"JR Sowers","year":"2001","journal-title":"Hypertension"},{"issue":"1","key":"pone.0253492.ref040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.HYP.0000078490.59735.6E","article-title":"Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension","volume":"42","author":"M Furuhashi","year":"2003","journal-title":"Hypertension"},{"issue":"5","key":"pone.0253492.ref041","first-page":"125","article-title":"Research progress on the biological effects of pancreatic RAAS system activation and blocking methods","volume":"13","author":"J Li","year":"2011","journal-title":"China Journal of Modern Medicine"},{"issue":"7","key":"pone.0253492.ref042","doi-asserted-by":"crossref","first-page":"e67192","DOI":"10.1371\/journal.pone.0067192","article-title":"Renin-angiotensin system blockers protect pancreatic islets against diet-induced obesity and insulin resistance in mice","volume":"8","author":"ED Frantz","year":"2013","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:14:03Z","timestamp":1625703243000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253492"}},"subtitle":[],"editor":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0253492","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,7]]}}}